Precision Pharmacotherapy for Paediatric Obesity: GLP-1 Receptor Agonists, Dual/Triple Agonists and MC4R-Targeted Therapy: A Structured Critical Narrative Review

Ashraf T. Soliman *

Department of Pediatrics, Division of Endocrinology, Hamad Medical Corporation (Hamad General Hospital), PO Box 3050, Doha, Qatar and Department of Pediatrics, Alexandria University, Alexandria, Egypt.

Fawzia Alyafei

Department of Pediatrics, Division of Endocrinology, Hamad Medical Corporation (Hamad General Hospital), PO Box 3050, Doha, Qatar.

Ahmed Khalil

Department of Pharmacology, Hamad Medical Corporation (Hamad General Hospital), P.O. Box 3050, Doha, Qatar.

Nada Alaaraj

Department of Pediatrics, Division of Endocrinology, Hamad Medical Corporation (Hamad General Hospital), PO Box 3050, Doha, Qatar.

Noor Hamed

Department of Pediatrics, Division of Endocrinology, Hamad Medical Corporation (Hamad General Hospital), PO Box 3050, Doha, Qatar.

Shayma Ahmed

Department of Pediatrics, Division of Endocrinology, Hamad Medical Corporation (Hamad General Hospital), PO Box 3050, Doha, Qatar.

*Author to whom correspondence should be addressed.


Abstract

Background: Obesity in children and adolescents has become a global clinical problem that lifestyle treatment alone rarely resolves. Glucagon-like peptide-1 receptor agonists, multi-receptor incretin agonists and melanocortin-4 receptor agonists have changed what pharmacotherapy can achieve, yet the evidence for each class has developed in separate literatures with different designs, populations and outcome measures.

Aim and Scope: This review evaluates whether current evidence supports a precision approach in which drug selection for children and adolescents is matched to the aetiology of obesity, developmental stage and comorbidity, rather than applied uniformly.

Methods: A structured critical narrative review was conducted using bibliographic databases, a clinical trial registry and citation tracking. Randomised and single-arm trials, observational cohorts, evidence syntheses, guidelines, genetic studies and mechanistic research were appraised qualitatively for design, applicability and certainty, and synthesised thematically.

Findings: In adolescents with common obesity, randomised evidence supports clinically meaningful reductions in body mass index with liraglutide and, to a greater extent, semaglutide, with emerging randomised evidence for liraglutide in younger children. Weight regain after discontinuation, the scarcity of randomised follow-up beyond the medium term and the inability of routine clinical characteristics to predict response limit confidence in long-term benefit. Evidence for dual and triple agonists in young people remains confined to youth-onset type 2 diabetes and registered trials, so current expectations rest on adult data. Melanocortin-4 receptor agonism with setmelanotide is best supported in biallelic deficiencies of the leptin–melanocortin pathway, Bardet–Biedl syndrome and acquired hypothalamic obesity, whereas benefit in heterozygous pathway variants and several syndromic conditions is unproven. Glucagon-like peptide-1 receptor agonists appear to retain efficacy in some monogenic and syndromic forms, but supporting data are small and largely uncontrolled.

Implications: Genetic and hypothalamic diagnosis currently offers the most defensible basis for stratified prescribing, while pharmacogenomic and phenotypic prediction remain investigational. Growth, bone health, eating disorder risk and inequitable access require prospective surveillance.

Conclusions: Precision pharmacotherapy for paediatric obesity is feasible for defined aetiological subgroups but remains aspirational for most children with common obesity. Long-term, developmentally informed trials with aetiological stratification are needed.

Keywords: Paediatric obesity, incretin-based therapy, semaglutide, tirzepatide, setmelanotide, melanocortin-4 receptor, hypothalamic obesity, precision medicine


How to Cite

Soliman, Ashraf T., Fawzia Alyafei, Ahmed Khalil, Nada Alaaraj, Noor Hamed, and Shayma Ahmed. 2026. “Precision Pharmacotherapy for Paediatric Obesity: GLP-1 Receptor Agonists, Dual Triple Agonists and MC4R-Targeted Therapy: A Structured Critical Narrative Review”. Journal of Advances in Medical and Pharmaceutical Sciences 28 (12):10-38. https://doi.org/10.9734/jamps/2026/v28i12915.

Downloads

Download data is not yet available.